Cadmium Exposure During Pregnancy and Fetal Growth

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18+
SponsorCentre Hospitalier Universitaire, Amiens

About this trial

Cadmium is a toxic heavy metal naturally present in the environment, whose human exposure has increased over recent decades due to diffuse anthropogenic contamination, particularly related to industrial activities and the use of mineral phosphate fertilizers in agriculture.

Cadmium is characterized by its bioaccumulative properties and well-established toxicity, including renal and bone damage and carcinogenic effects. In pregnant women, several animal and human cohort studies have shown that cadmium can cross the placental barrier and accumulate in placental tissue. Placental cadmium exposure has been associated with impaired placental function and adverse perinatal outcomes, including fetal growth restriction and increased neonatal morbidity. In the general population without occupational exposure, diet represents the main source of cadmium exposure, apart from tobacco smoking. Fetal growth, commonly assessed through birth weight adjusted for gestational age, is a major determinant of neonatal and long-term health outcomes. This monocentric prospective pilot study aims to assess fetal exposure to cadmium during pregnancy using placental cadmium concentration as a biomarker. Placental samples will be collected at delivery from women giving birth at Amiens University Hospital, and cadmium levels will be measured using inductively coupled plasma mass spectrometry. The association between placental cadmium concentration and fetal growth will be explored. Fetal growth will be evaluated using birth weight adjusted for gestational age, expressed as a standardized z-score. Maternal urinary and blood cadmium concentrations will also be measured to characterize maternal exposure and explore correlations between biological matrices. Placental efficiency, defined as the fetal-to-placental weight ratio, will be assessed as an indicator of placental function. The results of this pilot study will provide preliminary data to inform future larger-scale epidemiological and mechanistic studies on prenatal cadmium exposure and pregnancy outcomes.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Pregnant women aged 18 years or older

Singleton pregnancy

Planned delivery at the maternity unit of Amiens University Hospital (CHU Amiens)

Ability to receive study information and provide informed non-opposition/consent according to French regulations for non-interventional research

Disqualifiers

Women under legal protection measures, including guardianship, curatorship, or judicial safeguard

Inability to understand the study objectives or the constraints of the protocol (language barrier, cognitive impairment, or other reasons)

Lack of affiliation to a social security system, as required by French regulations

Trial population

Women delivering at term or preterm who are patients at Amiens University Hospital,

Trial design

Design model

Case-only

Time perspective

Prospective

Treatments tested in this trial

  • maternal blood samples

    Other intervention

    maternal blood samples are collected at admission for delivery as part of standard obstetric care.

  • Placental tissue samples

    Other intervention

    Placental tissue samples are collected at delivery,

  • maternal urine samples

    Other intervention

    maternal urine samples are obtained during routine prenatal visits,

Treatment groups

No treatment groups listed

Trial outcomes

Primary outcomes

1

association between placental cadmium levels and fetal growth

investigate the association between placental cadmium levels and fetal growth.

Time frame
at 2 months

Secondary outcomes

1

Association between maternal urinary cadmium concentration and fetal growth

Association between maternal urinary cadmium concentration (adjusted for creatinine) and fetal growth, assessed by birth weight adjusted for gestational age (z-score).

Time frame
at 2 months
2

Association between maternal blood cadmium concentration and fetal growth

Association between maternal blood cadmium concentration and fetal growth, assessed by birth weight adjusted for gestational age (z-score).

Time frame
at 2 months
3

Association between placental cadmium concentration and placental efficiency

Association between placental cadmium concentration and placental efficiency, defined as the fetal-to-placental weight ratio

Time frame
at 2 months
4

Association between maternal dietary patterns and estimated dietary cadmium intake and cadmium concentrations measured in placental tissue

Association between maternal dietary patterns and estimated dietary cadmium intake and cadmium concentrations measured in placental tissue

Time frame
at 2 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.